Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
EnviroGold Closes Upsized Unit Offering Raising $4.1M and Announces New Director (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Lixte Biotechnology Holdings Inc LIXT

Healthcare Biotechnology
Lixte Biotechnology Holdings, Inc. is a drug discovery company that uses biomarker technology to identify enzyme targets associated with serious common diseases and then designs novel compounds to attack those targets. The Company’s product pipeline is primarily focused on inhibitors of protein phosphatases, used alone and in combination with cytotoxic agents and/or x-ray and immune checkpoint blockers and encompasses two categories of compounds at various stages of pre-clinical and clinical development that has therapeutic potential not only for cancer but also for other debilitating and life-threatening diseases. It is focused on development activities of its LB-100 series of drugs. The LB-100 series consists of novel structures, which treat not only several types of cancer but also vascular and metabolic diseases. The LB-200 series contains compounds, which has the potential to be effective in its class and may be useful for the treatment of chronic hereditary diseases.


NDAQ:LIXT - Post by User

Lixte Biotechnology Holdings Inc
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(9)
•••
  • MikeTesterX
Post by MikeTesteron Aug 01, 2024 4:56pm
41 Views
Post# 36159146

Lixte Biotechnology Holdings, Inc. (LIXT): A Promising Prote

Lixte Biotechnology Holdings, Inc. (LIXT): A Promising Protehttps://beyondspx.com/2024/08/01/lixte-biotechnology-holdings-inc-lixt-a-promising-protein-phosphatase-2a-inhibitor-in-clinical-development/
<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities